CD33 and acute myeloid leukemia: Recent preclinical studies from other groups and ours have demonstrated that AMG 330 effectively redirects T-cells to destroy CD33+ AML cells [14–17]; of note, unlike bivalent antibodies, continuous exposure to AMG 330 at cytotoxic concentrations does not lead to down-modulation of CD33 expression on AML cells [16].